drugset / Trial / NCT06344715
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2022-10-17
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-I7 | Protein / enzyme biologic | 320 ug | Intramuscular |
| Subject | NT-I7 | Protein / enzyme biologic | 720 ug | Intramuscular |
| Subject | NT-I7 | Protein / enzyme biologic | 960 ug | Intramuscular |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | SL-T10 | Vaccine | 3 mg | Intramuscular |
| Subject | SL-T10 | Vaccine | 6 mg | Intramuscular |